A powerful bone-targeting drug can trigger a paradoxical, life-threatening mineral deficiency in multiple myeloma patients, according to a breakthrough case study. The report reveals that denosumab, a human monoclonal antibody widely used to prevent fractures, can cause a rare “hungry bone syndrome-like state” even in purely bone-destroying (osteolytic) cancers such as multiple myeloma.
The study, titled “Hungry Bone Syndrome-Like State Following Denosumab in a Patient with Multiple Myeloma” and published in JCEM Case Reports, details a severe metabolic crisis in a 76-year-old male patient with newly diagnosed multiple myeloma. The multidisciplinary clinical team, led by Ambrish Mithal, MD, at Max Super Specialty Hospital in New Delhi, India, documented that the patient experienced a catastrophic metabolic crash just one week after receiving his second monthly dose of denosumab.
The patient developed profound, prolonged hypocalcemia, alongside severe hypophosphatemia and hypomagnesemia. This multi-mineral depletion was accompanied by a dangerous elongation of his heart’s electrical cycle — known as QT interval prolongation — which left him highly vulnerable to fatal cardiac arrhythmias.
This clinical event directly challenges conventional oncology and endocrinology assumptions. Historically, true Hungry Bone Syndrome (HBS) is a prolonged mineral-draining phenomenon observed almost exclusively in two distinct clinical scenarios: Following a parathyroidectomy for hyperparathyroidism, where the sudden drop in parathyroid hormone causes an abrupt halt to bone resorption, or in advanced prostate cancer patients presenting with osteoblastic metastases, where new, unmineralized bone matrix is rapidly and aggressively laid down. Finding an HBS-like state in a multiple myeloma patient is highly unexpected and structurally counterintuitive. Myelomas typically feature purely osteolytic lesions — characterized by overactive osteoclasts that destroy the bone matrix — rather than pathways that aggressively mineralize it.
Moving forward, clinicians must implement rigorous pre-screening protocols and tight, long-term post-injection mineral monitoring — particularly for any cancer patient exhibiting compromised kidney function or extensive, high-burden osteolytic disease.
Clinical investigators discovered that the patient’s existing renal impairment, combined with extensive skeletal tumor involvement, created a perfect storm for the drug to backfire. Denosumab functions by binding to and inhibiting RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), which rapidly shuts down the activity of the body’s osteoclasts (the cells responsible for dissolving bone).
However, in this patient, the sudden cessation of bone resorption caused the massive volume of surrounding skeletal lesions to undergo rapid, uncontrolled remineralization. The bones essentially transformed into a massive structural “mineral sink,” continuously vacuuming calcium, magnesium, and phosphate straight out of the circulating blood supply to heal the extensive osteolytic cavities.
Compounding the crisis, the patient’s body attempted to compensate for the crashing serum levels by developing secondary hyperparathyroidism. This systemic feedback loop kept his bone turnover markers elevated, driving a vicious cycle that caused the profound mineral depletion to persist for weeks.
The resulting hypocalcemia proved highly refractory to standard treatments. It required aggressive, continuous interventions, including high-dose oral and intravenous calcium, active vitamin D (calcitriol) to maximize intestinal absorption, and heavy magnesium supplementation. Low urinary calcium levels ultimately confirmed the diagnosis, proving that the patient’s kidneys weren’t leaking the mineral; instead, his own skeleton was relentlessly absorbing the mineral from his blood. The medical authors concluded that while denosumab remains an invaluable asset for protecting the skeletal integrity and reducing skeletal-related events (SREs) in oncology patients, a one-size-fits-all dosing approach presents hidden risks. Moving forward, clinicians must implement rigorous pre-screening protocols and tight, long-term post-injection mineral monitoring — particularly for any cancer patient exhibiting compromised kidney function or extensive, high-burden osteolytic disease.
